Marta B. Davidson

Toronto, ON M5G2M9, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53.

Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53.

Journal: Current oncology (Toronto, Ont.)

Published: May 05, 2026

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.

Journal: Current oncology (Toronto, Ont.)

Published: January 06, 2026

What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?

What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?

Journal: Clinical lymphoma, myeloma & leukemia

Published: September 18, 2025

Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part Two - The team and patient care experiences.

Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part Two - The team and patient care experiences.

Journal: Canadian oncology nursing journal = Revue canadienne de nursing oncologique

Published: September 02, 2025

Title Not Found

Title Not Found

Journal: Canadian oncology nursing journal = Revue canadienne de nursing oncologique

Published: August 28, 2025

Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part One - From timeliness of triage to cost-saving.

Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part One - From timeliness of triage to cost-saving.

Journal: Canadian oncology nursing journal = Revue canadienne de nursing oncologique

Published: August 28, 2025

Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial.

Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial.

Journal: The Lancet. Haematology

Published: May 23, 2025

Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis.

Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis.

Journal: Blood cancer journal

Published: April 21, 2025

Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.

Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.

Journal: Blood advances

Published: December 24, 2024

Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms.

Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms.

Journal: Blood neoplasia

Published: December 19, 2024

Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML.

Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML.

Journal: Blood cancer journal

Published: July 18, 2024

Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML.

Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML.

Journal: European journal of haematology

Published: April 10, 2024

Showing 1-12 of 26

Last Updated: 09/26/2026